Application of the 3R Concept in the Production of European Antiviperinum on Horses – Multisite, Low Volumes Immunization Protocol and Elisa

Open access

Abstract

During time, both professionals and general public became aware of the importance of animal welfare. This term not only covers endangered wild animal species, animals used in food industry, pets and experimental animals, but also animals used in production of biologics. The implementation of the 3R concept (Replacement, Reduction and Refinement) is especially important in this type of production. In this article, we describe for the first time the low dose, low volume and multi-site immunization protocol, as well as appropriate ELISA we developed for production of European anti-viper (V. ammodytes, long horned) antivenom in horses, which can help to significantly improve the welfare of the used animals.

1. Gutierrez J, Calvete J, Habib A, Harrison R, Williams D, Warrell D: Snakebite envenoming. Nature Reviews Disease Primers 2017, 3:17063.

2. Chippaux JP: Snake-bites: appraisal of the global situation. Bulletin of the WHO 1998, 76(5): 515-524.

3. Kasturiratne A, Wickremasinghe AR, de Silva N, Gunawardena NK, Pathmeswaran A, Premaratna R, Savioli L, Lalloo DG, de Silva HJ: The Global Burden of Snakebite: A Literature Analysis and Modelling Based on Regional Estimates of Envenoming and Deaths. PLoS ONE 2008, 5:e218.

4. World Health Organization (WHO): Venomous snakes distribution and species risk categories. Geneva, Switzerland: WHO Press; 2010a. [http://apps.who.int/bloodproducts/snakeantivenoms/database/].

5. Lamb T, Haro L, Lonati D, Brvar M, Eddleston M: Antivenom for European Vipera species envenoming. Clinical Toxicology 2017, 55(6):557-568.

6. Moroz-Perlmutter C, Goldblum N, de Vries A, Gitter S: Detoxification of snake venoms and venom fractions by formaldehyde. Proceedings of the Society for Experimental Biology and Medicine 1963, 112:595–598.

7. World Health Organization (WHO): Guidelines for the production, control and regulation of snake antivenom immunoglobulins. Geneva, Switzerland: WHO Press; 2018. [http://www.who.int/bloodproducts/snake_antivenoms/snakeantivenomguide/en/].

8. World Health Organization (WHO): Guidelines for the Production, Control and Regulation of Snake Antivenom Immunoglobulins. Geneva, Switzerland: WHO Press; 2010b. [http://www.who.int/bloodproducts/snake_antivenoms/snakeantivenomguideline.pdf]

9. Freitas TV, Fortes-Dias CL, Diniz CR, Velarde DT, Freitas CF: Immunization of horses with Crotalus durissus terrificus (South American rattlesnake) venom. A comparison of four different procedures. Brazilian Journal of Medical and Biological Research 1991, 24:281–290.

10. Pratanaphon R, Akesowan S, Khow O, Sriprapat S, Ratanabanangkoon K: Production of highly potent horse antivenom against the Thai cobra (Naja kaouthia). Vaccine 1997, 15:1523–1528.

11. Chotwiwatthanakun C, Pratanaphon R, Akesowan S, Sriprapat S, Ratanabanangkoon K: Production of potent polyvalent antivenom against three elapid venoms using a low dose, low volume, multi-site immunization protocol. Toxicon 2001, 39:1487–1494.

12. Sriprapat S, Aeksowan S, Sapsutthipas S, Chotwiwatthanakun C, Suttijitpaisal P, Pratanaphon R, Khow O, Sitprija V, Ratanabanangkoon K: The impact of a low dose, low volume, multi-site ation on the production of therapeutic antivenoms in Thailand. Toxicon 2003, 41:57–64.

13. Sapsutthipas S, Leong PK, Akesowan S, Pratanaphon R, Tan NH, Ratanabanangkoon K: Effective equine imunization protocol for production of potent poly-specific antisera against Calloselasma rhodostoma, Cryptelytrops albolabris and Daboia siamensis. PLoS Neglected Tropical Diseasess 2015, 9:e0003609.

14. Artigas RS, Cruz AM, Martin OP, Baptista LA, Valdes DC, Pupo OM: Obtention of tetanus antitoxin hyperimmune sera in equines. International Journal of Current Research 2016, 8:36248-36253.

15. Shantavasinkul P, Tantawichien T, Jaijaroensup W, Lertjarutorn S, Banjongkasaena A, Wilde H, Sitprija V. A 4-Site, Single-Visit Intradermal Postexposure Prophylaxis Regimen for Previously Vaccinated Patients: Experiences with 15000 Patients. Clinical Infectious Diseases 2010, 51:1070-1072.

16. Council of Europe: European viper venom antiserum. In: European Pharmacopoeia 8.0. Strasbourg, France; 2014, 1033.

17. Halder M: Three Rs potential in the development and quality control of immunobiologicals. Alternatives to Animal Experimentation 2001, 18(Suppl. 1):13-47.

18. Russell WMS, Burch RL: The Principles of Humane Experimental Technique. London, United Kingdom: Methuen, 1959.

19. Zivkovic I, Rajnpreht I, Minic R, Mitic K, Aleksic I, Kadric J, Petrusic V: Characterization of Intor:Swiss albino mice adopted in the Institute of Virology, Vaccines and Sera – Torlak, Belgrade in the early twentieth century. Acta veterinaria – Belgrade 2016, 66(3):279-293.

20. European Medicines Agency (EMA): Note for guidance on validation of analytical procedures: text and methodology. ICH Harmonised Tripartite Guideline 2005. [http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf].

21. Pullen GR, Fitzgerald MG, Hosking CS: Antibody avidity determination by ELISA using thiocyanate elution. Journal Immunological Methods 1986, 86:83–87.

22. Russell FE. Snake venom immunology: historical and practical considerations. Journal of Toxicology: Toxin Reviews 1988, 7:1-82.

23. Kalyan kumar B, Nanda1 S, Venkateshwarlu1 P, Kiran kumarY, Jadhav RT: Antisnake Venom Serum (ASVS). International Journal on Pharmaceutical and Biomedical Research 2010, 1(3): 76-89.

24. Murray A, Lawrence GP: How should the repeatability of clinical measurements be analysed? An assessment of analysis techniques with data from cardiovascular autonomic function tests. Quarterly Journal of Medicine 1993, 86:831-836.

25. Biddlecombe RA, Law B: Validation of an immunoassay. In: Immunoassay: a Practical Guide. London, United Kingdom: Taylor & Francis Group; 1996, 179-192.

26. De Roodt A, Dolab JA, Segre L, Simoncini C, Hajos SE, Fernandez T, Dokmetjian JC, Litwin S, Accattoli C, Vidal JC: The Immunochemical Reactivity and Neutralizing Capacity of Polyvalent Vipera (European) Antivenom on Enzymatic and Toxic Activities in the Venoms of Crotalids from Argentina. Journal of Venomous Animals and Toxins 1999, 5:67-83.

27. Casewell NR, Al-Abdulla I, Smith D, Coxon R, Landon J: Immunological Cross-Reactivity and Neutralisation of European Viper Venoms with the Monospecific Vipera berus Antivenom ViperaTAb. Toxins (Basel) 2014, 6:2471-2482.

28. Stills HF Jr: Adjuvants and Antibody Production: Dispelling the Myths Associated withFreund’s Complete and Other Adjuvants. ILAR Journal 2005, 46:280-294.

29. Poulsen TR, Jensen A, Haurum JS, Andersen PS: Limits for Antibody Affinity Maturation and Repertoire Diversification in Hypervaccinated Humans. Journal of Immunology 2011, 187:4229-4235.

30. Maede Y, Inaba M, Amano Y, Murase T, Goto I, Itakura C: Cryoglobulinemia in a Horse. The Journal of Veterinary Medical Science 1991, 53:379-383.

31. Theakston RDG, Reid HA: Enzyme linked immunosorbent assay (ELISA) in assessing antivenom potency. Toxicon 1979, 17:511-515.

32. Rungsiwongse J, Ratanabamamgkoon K: Development of an ELISA to assess the potency of horse therapeutic antivenom against Thai cobra venom. Journal of Immunological Methods 1991, 136:37-43.

33. Ibrahim NM, Farid NM: Comparison between Two In Vitro ELISA-Based Assays in the Determination of Antivenom Potency. Journal of Applied Sciences Research 2009, 5:1223-1229.

34. Georgieva D, Risch M, Kardas A, Buck F, von Bergen M, Betzel C: Comparative Analysis of the Venom Proteomes of Vipera ammodytes ammodytes and Vipera ammodytes meridionalis. Journal of Proteome Research 2008, 7:866–886.

35. Halassy B, Brgles M, Habjanec L, Lang Balija M, Kurtovic T, Marchetti-Deschmann M, Krizaj I, Allmaier G: Intraspecies variability in Vipera ammodytes ammodytes venom related to its toxicity and immunogenic potential. Comparative Biochemistry and Physiology, Part C 2011, 153:223–230.

36. Halassy B, Habjanec L, Brgles M, Lang Balija M, Leonardi A, Kovacic L, Prijatelj P, Tomasic J, Krizaj I: The role of antibodies specific for toxic sPLA2s and haemorrhagins in neutralizing potential of antisera raised against Vipera ammodytes ammodytes venom. Comparative Biochemistry and Physiology - Part C: Toxicology & Pharmacology 2008, 148:178-83.

37. Theakson RDG, Warrell DA, Griffiths E: Report of a WHO workshop on the standardization and control of antivenoms. Toxicon 2003, 41: 541-557.

Acta Veterinaria

The Journal of University of Belgrade

Journal Information

IMPACT FACTOR 2017: 0.604
5-year IMPACT FACTOR: 0.439

CiteScore 2017: 0.65

SCImago Journal Rank (SJR) 2017: 0.287
Source Normalized Impact per Paper (SNIP) 2017: 0.608

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 58 58 18
PDF Downloads 40 40 10